Serology


Last updated: 2021 Sep 13
Total hit(s): 10
Select item(s)
Key Findings
Comments
(You can add your comments too!)
Original Article
(hover to see details)
Antibodies from vaccinated, convalescent individuals and critical COVID-19 patients was used to test the neutralising capacity aginst different SARS-CoV-2 variants. The convalescent and critical COVID-19 patients showed no significant change in the neutralsing capacity against the wild type and B.1.1.241 variant, however, a significant decrease in neutralisation against the Alpha variant (B.1.1.7) was observed. All participants showed a decrease in the neutralisation against the Beta variant (B.1.351). The large time disparities between the three examined populations in terms of post-infection or immunisation limit the interpretation of the differences in results between the three groups.
34176436
(Emerg Microbes Infect)
PMID
34176436
Date of Publishing: 2021 Dec
Title Live virus neutralisation testing in convalescent patients and subjects vaccinated against 19A, 20B, 20I/501Y.V1 and 20H/501Y.V2 isolates of SARS-CoV-2
Author(s) nameSaade C, Gonzalez C et al.
Journal Emerg Microbes Infect
Impact factor
5.84
Citation count: 3
Date of Entry 2021 Sep 13


The neutralizing ability of sera from the vaccinated individuals (Pfizer vaccine) against different SARS-CoV-2 spike variants was determined. There was no significant change in the neutralising activity against the wildtype (USA-WA1/2020), B.1.1.7-spike+ E484K and B.1.526-spike viruses. The neutralization of B.1.429-spike was slightly lower. Despite repeated alterations, the majority of newly developed SARS-CoV-2 variants are vulnerable to the vaccine-elicited immune response, emphasising the significance of widespread vaccination to combat the Covid pandemic.
-
()
PMID
-
Date of Publishing: 2021 Jul 29
Title BNT162b2 - Elicited Neutralization against New SARS-CoV-2 Spike Variants
Date of Entry 2021 Sep 13


The NVX-CoV2373 vaccine was efficacious and induced some cross-protection against infection caused by the SARS-CoV-2 beta variant (B.1.351). Among the HIV negative participants, the post-hoc vaccine efficacy against the beta variant was 51%.
33951374
(N Engl J Med)
PMID
33951374
Date of Publishing: 2021 May 5
Title Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant
Author(s) nameShinde V, Bhikha S et al.
Journal N Engl J Med
Impact factor
37.91
Citation count: 11
Date of Entry 2021 Sep 13


The efficacy of the Pfizer BNT-162b2 vaccine against SARS-CoV-2 mutants (RBD) was tested in convalescent, uninfected and vaccinated individuals. Vaccinated individuals showed a robust humoral response with high IgG antibody titers, however, they had reduced neutralizing activity against Beta variant (B.1.351) of SARS-CoV-2. Future vaccines should focus on the most prevailing RBD mutations of SARS-CoV-2 variants which are bypassing the existing strategies.
34035301
(Nat Commun)
PMID
34035301
Date of Publishing: 2021 May 25
Title Immune response to SARS-CoV-2 variants of concern in vaccinated individuals
Author(s) nameBecker M, Dulovic A et al.
Journal Nat Commun
Impact factor
11.8
Citation count: 2
Date of Entry 2021 Sep 13


The neutralizing ability of the Sputnik V vaccine against B.1.1.7 and B.1.351 variants was determined by examining serum samples of the Sputnik V vaccine recipients. The majority of the samples showed good neutralising potency against the wild type and Alpha variants of SARS-CoV-2. However, the same set of sera showed moderate or very low activity against E484K substitution alone as well as for B.1.351 variant. Updated vaccines may be beneficial for the control of some emergent SARS-CoV-2 variants.
33851150
(Res Sq)
PMID
33851150
Date of Publishing: 2021 Apr 8
Title Neutraizing activity of Sputniv V vaccine sera against SARS-CoV-2 variants
Author(s) nameIkegame S, Siddiquey M et al.
Journal Res Sq
Impact factor
Cant find
Citation count: 1
Date of Entry 2021 Sep 13


In individuals vaccinated either with BNT162b2 or ChAdOx1, there was a significant reduction of neutralisation of B.1.617.1, B.1.617.2 and B.1.351 variants by 4.31, 5.11 and 6.29-folds respectively when compared to the Wuhan-Hu-1 variant. The mean antibody titres against the 3 VOCs analysed was higher in sera of individuals vaccinated with BNT162b2 when compared to ChAdOx1. Two doses of the Pfizer vaccine induced higher neutralising antibody titres against the Wuhan-hu-1 and the 3 VOCs compared to a single dose of BNT162b2 or two doses of the ChAdOx1 vaccine.
-
()
PMID
-
Date of Publishing: 2021 Jun 28
Title Reduced neutralisation of the Delta (B.1.617.2) SARS-CoV-2 variant of concern following vaccination
Date of Entry 2021 Aug 6


Convalescent patients showed a 4-6.7-fold decrease whereas vaccinated recipients showed a 2-fold decrase in the neutralizing antibody titre to the Epsilon variant, indicating a moderate resistance to the antibodies produced by the individuals. The Epsilon variant requires close monitoring and future research to combat its ability to decrease vaccine effectiveness due to accumulation of mutations.
33991487
(Cell)
PMID
33991487
Date of Publishing: 2021 Jun 24
Title Transmission, infectivity, and neutralization of a spike L452R SARS-CoV-2 variant
Author(s) nameDeng X, Garcia-Knight MA et al.
Journal Cell
Impact factor
27.35
Citation count: 6
Date of Entry 18_36_32 Jul


The long term durability of antibodies from individuals vaccinated with the mRNA-1273 vaccine was assessed. The neutralising activity against variant B.1.351 fell below 20 GMT (Geometric mean titre) after 100 days, P.1 after 202 days, variant B.1.429 after 258 days and B.1.1.7 after 309 days. The m-RNA-1273 two-dose vaccine should protect induviduals from all variants for up to a year
-
()
PMID
-
Date of Publishing: 2021 May 04
Title Modeling and Predicting Antibody Durability for mRNA-1273 Vaccine for SARS-CoV-2 Variants
Date of Entry 18_36_32 Jul


A two-dose regimen of the BBV152 (Covaxin) vaccine significantly increased the IgG titre and neutralizing activity against the B.1.1.28.2 and D614 varaints in vaccinated individuals when compared to convalescent sera.
-
()
PMID
-
Date of Publishing: 2021 Apr 30
Title Neutralization of B.1.1.28 P2 variant with sera of natural SARS-CoV-2 infection and recipients of BBV152 vaccine
Date of Entry 18_36_32 Jul


The plasma from COVID-19 convalescent individuals showed a 6-fold decrease in the neutralisation potential for P1 lineage (P.1/12 and P.1/30) when compared to the B lineage. Plasma samples from CoronoVac vaccinated individuals failed to neutralise the P1 lineage isolates The SARS-CoV-2 P1 lineage can escape from neutralisation antibodies produced in individuals after a natural infection with previously circulating variants or vaccination.
-
()
PMID
-
Date of Publishing: 2021 Mar 01
Title Levels of SARS-CoV-2 Lineage P.1 Neutralization by Antibodies Elicited after Natural Infection and Vaccination
Date of Entry 18_36_32 Jul